
Zynerba Pharmaceuticals Presenting Data from Phase 2 BRIGHT Trial
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE is presenting a poster describing data from the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a …
Read More